Emmanouil Tsochatzis

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/33131/publications.pdf

Version: 2024-02-01

390 papers	18,095 citations	23500 58 h-index	15683 125 g-index
407 all docs	407 docs citations	407 times ranked	17579 citing authors

#	Article	IF	Citations
1	The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism: Clinical and Experimental, 2016, 65, 1038-1048.	1.5	1,977
2	Liver cirrhosis. Lancet, The, 2014, 383, 1749-1761.	6.3	1,425
3	Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining Prognosis. Gastroenterology, 2010, 139, 1246-1256.e5.	0.6	905
4	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 156, 1717-1730.	0.6	777
5	EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology, 2016, 64, 433-485.	1.8	744
6	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis â€“ 2021 update. Journal of Hepatology, 2021, 75, 659-689.	1.8	676
7	Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy. Journal of Hepatology, 2011, 54, 650-659.	1.8	610
8	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 362-373.	3.7	411
9	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
10	Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 71, 371-378.	1.8	301
11	Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis. Liver International, 2012, 32, 919-927.	1.9	284
12	Systematic review: portal vein thrombosis in cirrhosis. Alimentary Pharmacology and Therapeutics, 2010, 31, 366-374.	1.9	261
13	Liver transplantation for acute liver failure in Europe: Outcomes over 20years from the ELTR database. Journal of Hepatology, 2012, 57, 288-296.	1.8	236
14	Malnutrition and sarcopenia predict postâ€liver transplantation outcomes independently of the Model for Endâ€stage Liver Disease score. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 113-121.	2.9	236
15	Renal failure and cirrhosis: A systematic review of mortality and prognosis. Journal of Hepatology, 2012, 56, 810-818.	1.8	232
16	Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology, 2017, 66, 1980-1988.	3.6	223
17	Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 1193-1199.	1.8	184
18	Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices. Journal of Hepatology, 2016, 65, 899-905.	1.8	183

#	Article	IF	Citations
19	Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut, 2020, 69, 1173-1192.	6.1	182
20	The Evolving Role of Leptin and Adiponectin in Chronic Liver Diseases. American Journal of Gastroenterology, 2006, 101, 2629-2640.	0.2	168
21	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. Gastroenterology, 2018, 154, 1694-1705.e4.	0.6	162
22	Tacrolimus Trough Levels, Rejection and Renal Impairment in Liver Transplantation: A Systematic Review and Meta-Analysis. American Journal of Transplantation, 2012, 12, 2797-2814.	2.6	137
23	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology, 2021, 6, 185-198.	3.7	130
24	Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-410.	1.3	130
25	MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation. Hepatology, 2018, 68, 172-186.	3.6	129
26	Investigation and management of a raised serum ferritin. British Journal of Haematology, 2018, 181, 331-340.	1.2	126
27	A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. British Journal of Cancer, 2013, 108, 1252-1259.	2.9	121
28	Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. Journal of Hepatology, 2014, 60, 948-954.	1.8	119
29	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	1.8	114
30	Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. Journal of Hepatology, 2021, 74, 1109-1116.	1.8	112
31	Adrenocortical dysfunction in liver disease: A systematic review. Hepatology, 2012, 55, 1282-1291.	3.6	110
32	Risk factors for recurrent primary sclerosing cholangitis after liver transplantation. Journal of Hepatology, 2015, 63, 1139-1146.	1.8	110
33	New therapeutic paradigm for patients with cirrhosis. Hepatology, 2012, 56, 1983-1992.	3.6	108
34	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 2022, 75, 219-228.	3.6	107
35	Non-alcoholic fatty liver disease and the interface between primary and secondary care. The Lancet Gastroenterology and Hepatology, 2018, 3, 509-517.	3.7	106
36	Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. Mediators of Inflammation, 2009, 2009, 1-8.	1.4	105

#	Article	IF	Citations
37	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. American Journal of Gastroenterology, 2021, 116, 723-732.	0.2	105
38	Early tacrolimus exposure after liver transplantation: Relationship with moderate/severe acute rejection and long-term outcome. Journal of Hepatology, 2013, 58, 262-270.	1.8	99
39	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. Journal of Hepatology, 2020, 72, 1140-1150.	1.8	97
40	Non-invasive assessment of liver fibrosis. Annals of Gastroenterology, 2012, 25, 218-231.	0.4	93
41	Intentionâ€toâ€treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology, 2017, 66, 1910-1919.	3.6	91
42	Azathioprine in Liver Transplantation: A Reevaluation of Its Use and a Comparison with Mycophenolate Mofetil. American Journal of Transplantation, 2009, 9, 1725-1731.	2.6	90
43	Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. American Journal of Gastroenterology, 2017, 112, 588-596.	0.2	82
44	Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease. BMC Gastroenterology, 2019, 19, 122.	0.8	81
45	Serum adipokine levels in chronic liver diseases: Association of resistin levels with fibrosis severity. Scandinavian Journal of Gastroenterology, 2008, 43, 1128-1136.	0.6	78
46	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€illness analysis. Liver International, 2021, 41, 1227-1242.	1.9	76
47	Assessment of adrenocortical reserve in stable patients with cirrhosis. Journal of Hepatology, 2011, 54, 243-250.	1.8	75
48	Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation. Liver Transplantation, 2011, 17, 178-188.	1.3	74
49	Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 3069.	1.4	74
50	A Novel Immunological Assay for Hepcidin Quantification in Human Serum. PLoS ONE, 2009, 4, e4581.	1.1	72
51	Defining comprehensive models of care for NAFLD. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 717-729.	8.2	72
52	The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer, 2008, 61, 391-397.	0.9	69
53	International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation. Transplantation, 2019, 103, 45-56.	0.5	69
54	Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Annals of Translational Medicine, 2017, 5, 40-40.	0.7	67

#	Article	IF	Citations
55	Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. The Cochrane Library, 2015, 1, CD010542.	1.5	66
56	Gender differences in liver disease and the drug-dose gender gap. Pharmacological Research, 2017, 120, 97-108.	3.1	66
57	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. American Journal of Gastroenterology, 2019, 114, 446-452.	0.2	65
58	Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2008, 27, 80-89.	1.9	62
59	Primary biliary cirrhosis after liver transplantation: Influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transplantation, 2010, 16, 64-73.	1.3	60
60	Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1227-1232.	1.4	59
61	Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology, 2014, 60, 832-843.	3.6	59
62	Management of people with early- or very early-stage hepatocellular carcinoma. The Cochrane Library, 2017, 3, CD011650.	1.5	59
63	Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal. Transplant International, 2016, 29, 961-973.	0.8	57
64	Systematic review with metaâ€analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. Alimentary Pharmacology and Therapeutics, 2016, 43, 575-585.	1.9	57
65	Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. Journal of Hepatology, 2013, 58, 962-968.	1.8	56
66	Transarterial embolization as neoâ€adjuvant therapy pretransplantation in patients with hepatocellular carcinoma. Liver International, 2013, 33, 944-949.	1.9	55
67	Collagen proportionate area is an independent predictor of longâ€term outcome in patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 1214-1222.	1.9	55
68	Elastography methods for the non-invasive assessment of portal hypertension. Expert Review of Gastroenterology and Hepatology, 2018, 12, 155-164.	1.4	54
69	Insulin resistance and metabolic syndrome in chronic liver diseases: Old entities with new implications. Scandinavian Journal of Gastroenterology, 2009, 44, 6-14.	0.6	53
70	Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C. Journal of Viral Hepatitis, 2010, 17, 800-806.	1.0	53
71	Nine scoring models for shortâ€term mortality in alcoholic hepatitis: crossâ€validation in a biopsyâ€proven cohort. Alimentary Pharmacology and Therapeutics, 2014, 39, 721-732.	1.9	53
72	Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count. Transplant International, 2012, 25, 555-563.	0.8	52

#	Article	IF	Citations
73	Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The royal free hospital cirrhosis glomerular filtration rate. Hepatology, 2017, 65, 582-591.	3.6	52
74	Hepatocellular Carcinoma. New England Journal of Medicine, 2012, 366, 92-93.	13.9	50
75	Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS). Digestive Diseases and Sciences, 2019, 64, 1335-1345.	1.1	50
76	Referral pathways for patients with NAFLD based on nonâ€invasive fibrosis tests: Diagnostic accuracy and cost analysis. Liver International, 2019, 39, 2052-2060.	1.9	49
77	Evaluating the association of serum ferritin and hepatic iron with disease severity in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 1325-1334.	1.9	48
78	Review article: nonâ€alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Alimentary Pharmacology and Therapeutics, 2021, 54, 1013-1025.	1.9	47
79	Transarterial Chemoembolization, Transarterial Chemotherapy, and Intra-arterial Chemotherapy for Hepatocellular Carcinoma Treatment. Seminars in Oncology, 2010, 37, 89-93.	0.8	46
80	Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver International, 2014, 34, 1452-1463.	1.9	46
81	Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: A comparative approach with genotype 1 chronic hepatitis C. Digestive and Liver Disease, 2007, 39, 936-942.	0.4	45
82	Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transplant International, 2010, 23, 861-870.	0.8	45
83	Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. Digestive and Liver Disease, 2016, 48, 1471-1477.	0.4	45
84	Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism: Clinical and Experimental, 2020, 113, 154413.	1.5	45
85	Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scandinavian Journal of Gastroenterology, 2009, 44, 752-759.	0.6	44
86	Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	41
87	Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection. Gut, 2007, 57, 500-506.	6.1	40
88	Serum Apoptotic Caspase Activity in Chronic Hepatitis C and Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2010, 44, e87-e95.	1.1	40
89	Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology and Hepatology, 2017, 11, 357-369.	1.4	40
90	Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-10.	0.8	40

#	Article	IF	Citations
91	Hepatic Steatosis in Genotype 4 Chronic Hepatitis C Is Mainly Because of Metabolic Factors. American Journal of Gastroenterology, 2007, 102, 634-641.	0.2	39
92	Sarcopenia Does Not Worsen Survival in Patients With Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. American Journal of Gastroenterology, 2020, 115, 1911-1914.	0.2	38
93	Review article: the extraâ€skeletal effects of vitamin <scp>D</scp> in chronic hepatitis <scp>C</scp> infection. Alimentary Pharmacology and Therapeutics, 2012, 35, 634-646.	1.9	37
94	Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within milan criteria. Liver Transplantation, 2014, 20, 1327-1335.	1.3	37
95	Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and longâ€term outcomes. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 61-69.	0.7	37
96	The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones, 2018, 17, 219-229.	0.9	37
97	Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update. Hepatology Communications, 2021, 5, 1824-1832.	2.0	37
98	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD). The Cochrane Library, 2017, 2017, CD011640.	1.5	36
99	Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. The Cochrane Library, 2017, 2017, CD011639.	1.5	35
100	Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2019, 2019, CD013103.	1.5	35
101	Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis. World Journal of Gastroenterology, 2015, 21, 3020.	1.4	35
102	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. The Lancet Gastroenterology and Hepatology, 2022, 7, 755-769.	3.7	34
103	Nonâ€selective betaâ€blockers are not associated with increased mortality in cirrhotic patients with ascites. Liver International, 2017, 37, 1334-1344.	1.9	33
104	Diagnosis and therapy of genetic haemochromatosis (review and 2017 update). British Journal of Haematology, 2018, 181, 293-303.	1.2	33
105	Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29â€year cohort study. Alimentary Pharmacology and Therapeutics, 2013, 38, 1354-1364.	1.9	32
106	Individualized care for portal hypertension: Not quite yet. Journal of Hepatology, 2015, 63, 543-545.	1.8	32
107	Management of metabolic syndrome and cardiovascular risk after liver transplantation. The Lancet Gastroenterology and Hepatology, 2019, 4, 731-741.	3.7	32
108	Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. Hepatology, 2020, 71, 627-642.	3.6	32

#	Article	IF	Citations
109	Global Epidemiology of Hepatitis B Virus (HBV) Infection. Current Hepatology Reports, 2015, 14, 171-178.	0.4	31
110	Biomarkers of bacterial translocation in advanced chronic liver disease: the key to individualizing prognosis. Annals of Gastroenterology, 2016, 29, 1-2.	0.4	31
111	Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. Hepatology, 2020, 71, 569-582.	3.6	30
112	Lack of agreement for defining â€˜clinical suspicion of rejectionâ€™ in liver transplantation: a model to select candidates for liver biopsy. Transplant International, 2015, 28, 455-464.	0.8	29
113	Loss of histone macroH2A1 in hepatocellular carcinoma cells promotes paracrine-mediated chemoresistance and CD4⁺CD25⁺FoxP3⁺ regulatory T cells activation. Theranostics, 2020, 10, 910-924.	4.6	29
114	Metabolic and cardiovascular complications in the liver transplant recipient. Annals of Gastroenterology, 2015, 28, 183-192.	0.4	29
115	Collagen proportionate area predicts clinical outcomes in patients with alcoholâ€related liver disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1728-1739.	1.9	27
116	Sample size requirement for digital image analysis of collagen proportionate area in cirrhotic livers. Histopathology, 2013, 62, 421-430.	1.6	26
117	Bleeding Risk with Invasive Procedures in Patients with Cirrhosis and Coagulopathy. Current Gastroenterology Reports, 2017, 19, 45.	1.1	26
118	Downstaging for hepatocellular cancer: harm or benefit?. Translational Gastroenterology and Hepatology, 2017, 2, 106-106.	1.5	26
119	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World Journal of Gastroenterology, 2015, 21, 11044.	1.4	25
120	Antiviral therapy for recurrent liver graft infection with hepatitis C virus. , 2010, , CD006803.		24
121	Diagnosis and treatment of ascites. Journal of Hepatology, 2017, 67, 184-185.	1.8	24
122	The Intentionâ€toâ€Treat Effect of Bridging Treatments in the Setting of Milan Criteriaâ€“In Patients Waiting for Liver Transplantation. Liver Transplantation, 2019, 25, 1023-1033.	1.3	24
123	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. Journal of Hepatology, 2022, 76, 265-274.	1.8	24
124	Transarterial chemoembolisation is not superior to embolisation alone: The recent European Association for the Study of the Liver (EASL)â€“European Organisation for Research and Treatment of Cancer (EORTC) guidelines. European Journal of Cancer, 2013, 49, 1509-1510.	1.3	23
125	Prolonging Survival in Patients With Cirrhosis: Old Drugs With New Indications. Gastroenterology, 2010, 139, 1813-1815.e1.	0.6	22
126	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterology, 2017, 8, 252-259.	0.9	22

#	Article	IF	Citations
127	Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study. Alimentary Pharmacology and Therapeutics, 2009, 30, 947-954.	1.9	21
128	Pharmacological interventions for primary sclerosing cholangitis. The Cochrane Library, 2017, 2017, CD011343.	1.5	21
129	Pharmacological interventions for primary biliary cholangitis. The Cochrane Library, 2017, 2017, CD011648.	1.5	21
130	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. Minerva Endocrinology, 2017, 42, 184-194.	0.6	21
131	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. The Cochrane Library, 2020, 1, CD013125.	1.5	21
132	Glucocorticosteroids for people with alcoholic hepatitis. The Cochrane Library, 2017, 11, CD001511.	1.5	20
133	Monocyte-macrophage activation is associated with nonalcoholic fatty liver disease and liver fibrosis in HIV monoinfection independently of the gut microbiome and bacterial translocation. Aids, 2019, 33, 805-814.	1.0	20
134	Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154291.	1.5	20
135	Systematic Review and Meta-analysis: The Role of Diet in the Development of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2023, 21, 1462-1474.e24.	2.4	20
136	Angioimmunoblastic T-Cell Lymphoma-Associated Arthritis. Journal of Clinical Rheumatology, 2005, 11, 326-328.	0.5	19
137	Future treatments of cirrhosis. Expert Review of Gastroenterology and Hepatology, 2014, 8, 571-581.	1.4	19
138	Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 0, , .	1.5	19
139	Case-finding strategies in non-alcoholic fatty liver disease. JHEP Reports, 2021, 3, 100219.	2.6	19
140	Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut, 2014, 63, 1005-1013.	6.1	18
141	Cardiovascular morbidity and mortality is increased postâ€liver transplantation even in recipients with no preâ€existing risk factors. Liver International, 2019, 39, 1557-1565.	1.9	18
142	Etiology and Severity of Liver Disease in HIV-Positive Patients With Suspected NAFLD: Lessons From a Cohort With Available Liver Biopsies. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 474-480.	0.9	18
143	Longâ€term followâ€up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. Clinical Transplantation, 2011, 25, 614-624.	0.8	17
144	Ultrasonography for diagnosis of alcoholic cirrhosis in people with alcoholic liver disease. The Cochrane Library, 2016, 3, CD011602.	1.5	17

#	Article	IF	Citations
145	Costâ€effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the <scp>UK</scp>: systematic review and economic evaluation. Journal of Viral Hepatitis, 2016, 23, 139-149.	1.0	17
146	The Royal Free Hospital â€˜hub-and-spoke network modelâ€™ delivers effective care and increased access to liver transplantation. Public Health, 2018, 154, 164-171.	1.4	17
147	Top research priorities in liver and gallbladder disorders in the UK. BMJ Open, 2019, 9, e025045.	0.8	17
148	Area Under Trough Concentrations of Tacrolimus as a Predictor of Progressive Renal Impairment After Liver Transplantation. Transplantation, 2019, 103, 2539-2548.	0.5	17
149	Carvedilolâ€”the best Î²-blocker for primary prophylaxis?. Nature Reviews Gastroenterology and Hepatology, 2009, 6, 692-694.	8.2	16
150	Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. European Journal of Gastroenterology and Hepatology, 2016, 28, 786-791.	0.8	16
151	Management of people with intermediate-stage hepatocellular carcinoma. The Cochrane Library, 2017, 3, CD011649.	1.5	16
152	New Drugs for NASH and HIV Infection: Great Expectations for a Great Need. Hepatology, 2020, 71, 1831-1844.	3.6	16
153	Neuroimaging correlates of brain injury in Wilsonâ€™s disease: a multimodal, whole-brain MRI study. Brain, 2022, 145, 263-275.	3.7	16
154	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. European Journal of Health Economics, 2021, 22, 505-518.	1.4	16
155	Liver test abnormalities in patients with HIV mono-infection: assessment with simple noninvasive fibrosis markers. Annals of Gastroenterology, 2017, 30, 349-356.	0.4	16
156	Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS ONE, 2021, 16, e0260313.	1.1	16
157	Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines. Journal of Hepatology, 2009, 51, 1084-1085.	1.8	15
158	Statins in cirrhosisâ€”Ready for prime time. Hepatology, 2017, 66, 697-699.	3.6	15
159	Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: hematemesis versus melena without hematemesis. European Journal of Gastroenterology and Hepatology, 2019, 31, 1334-1341.	0.8	15
160	Plasma Neurofilament Light as a Biomarker of Neurological Involvement in Wilson's Disease. Movement Disorders, 2021, 36, 503-508.	2.2	15
161	Non-alcoholic fatty liver disease: Current therapeutic options. Current Opinion in Pharmacology, 2021, 61, 98-105.	1.7	15
162	The paradigm shift from <scp>NAFLD</scp> to <scp>MAFLD</scp>: A global primary care viewpoint. Liver International, 2022, 42, 1259-1267.	1.9	15

#	Article	IF	Citations
163	Transaminase abnormalities and adaptations of the liver lobule manifest at specific cut-offs of steatosis. Scientific Reports, 2017, 7, 40977.	1.6	14
164	Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. Clinical Infectious Diseases, 2021, 73, e2184-e2193.	2.9	14
165	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013155.	1.5	14
166	Transarterial Therapies for Hepatocellular Carcinoma. Recent Results in Cancer Research, 2013, 190, 195-206.	1.8	14
167	Which transarterial therapy is best for hepatocellular carcinoma? â€“ The evidence to date. Journal of Hepatology, 2010, 53, 588.	1.8	13
168	Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. , 2010, , CD006573.		13
169	Is there any progress in the treatment of non-alcoholic fatty liver disease?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2011, 2, 1.	0.6	13
170	Validating non-invasive markers of fibrosis: the need for a new histological reference standard. Gut, 2011, 60, 1442-1443.	6.1	13
171	HCV in liver transplantation. Seminars in Immunopathology, 2013, 35, 101-110.	2.8	13
172	Transfusion strategies in patients with cirrhosis: less is more. Liver International, 2016, 36, 503-504.	1.9	13
173	An objective definition for clinical suspicion of Tâ€cellâ€mediated rejection after liver transplantation. Clinical Transplantation, 2017, 31, e13005.	0.8	13
174	Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease). The Cochrane Library, 2017, 2017, CD011646.	1.5	13
175	Comparison and correlation of fibrosis stage assessment by collagen proportionate area (CPA) and the ELF panel in patients with chronic liver disease. Digestive and Liver Disease, 2019, 51, 1001-1007.	0.4	13
176	Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013156.	1.5	13
177	ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2014, 3, 415-8.	0.7	13
178	Prognosis and treatment of patients with acute alcoholic hepatitis. Expert Review of Gastroenterology and Hepatology, 2014, 8, 471-486.	1.4	12
179	Beta-blockers in cirrhosis: Therapeutic window or an aspirin for all?. Journal of Hepatology, 2014, 61, 449-450.	1.8	12
180	Pharmacological interventions for acute hepatitis B infection. The Cochrane Library, 2017, 2017, CD011645.	1.5	12

#	Article	IF	Citations
181	Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. The Cochrane Library, 2020, 1, CD013203.	1.5	12
182	Incidence and outcome of colorectal cancer in liver transplant recipients: A national, multicentre analysis on 8115 patients. Liver International, 2019, 39, 353-360.	1.9	11
183	Non-alcoholic fatty liver disease (NAFLD) and the quest for effective treatments. Hepatobiliary Surgery and Nutrition, 2019, 8, 77-79.	0.7	11
184	Glucocorticosteroids for people with alcoholic hepatitis. The Cochrane Library, 2019, 2019, CD001511.	1.5	11
185	Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2020, 1, CD013123.	1.5	11
186	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 235-245.	0.5	11
187	A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology and Therapeutics, 2022, 55, 234-243.	1.9	11
188	Myelodysplastic syndrome presenting as acquired ichthyosis. European Journal of Internal Medicine, 2006, 17, 368-369.	1.0	10
189	Primary prevention of variceal haemorrhage: A pharmacological approach. Journal of Hepatology, 2010, 52, 946-948.	1.8	10
190	Noninvasive assessment of liver fibrosis: The need for better validation. Hepatology, 2011, 53, 1781-1782.	3.6	10
191	Reducing Early Exposure to Calcineurin Inhibitors: The Key Factor for a Successful Renal Sparing Strategy. American Journal of Transplantation, 2013, 13, 239.	2.6	10
192	Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013122.	1.5	10
193	Assessment of clinically significant portal hypertension by twoâ€dimensional shear wave elastography. European Journal of Clinical Investigation, 2022, 52, e13750.	1.7	10
194	Natural history of NAFLD: knowns and unknowns. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 151-152.	8.2	10
195	Prophylactic and therapeutic use of recombinant activated factor VII in patients with cirrhosis and coagulation impairment. Digestive and Liver Disease, 2007, 39, 490-494.	0.4	9
196	Smoking is associated with histological severity in nonalcoholic steatohepatitis. Hepatology, 2010, 52, 1522-1523.	3.6	9
197	Tacrolimus Exposure After Liver Transplantation in Randomized Controlled Trials: Too Much for Too Long. American Journal of Transplantation, 2013, 13, 1371-1372.	2.6	9
198	Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. Internal and Emergency Medicine, 2016, 11, 905-916.	1.0	9

#	Article	IF	Citations
199	Establishing Reliability Criteria for Liver ElastPQ Shear Wave Elastography (ElastPQ-SWE): Comparison Between 10, 5 and 3 Measurements. Ultraschall in Der Medizin, 2021, 42, 204-213.	0.8	9
200	Noninvasive assessment of liver fibrosis: The clinical context and question are important. Hepatology, 2011, 54, 2277-2277.	3.6	8
201	Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. The Cochrane Library, 2013, , CD006573.	1.5	8
202	Assessing liver disease in HIVâ€“HCV coinfected patients. Current Opinion in HIV and AIDS, 2015, 10, 316-322.	1.5	8
203	Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology. European Journal of Gastroenterology and Hepatology, 2015, 27, 313-320.	0.8	8
204	Treatment of severe alcoholic hepatitis: A systematic review. Current Opinion in Pharmacology, 2021, 60, 91-101.	1.7	8
205	The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. The Cochrane Library, 2022, 2022, CD013345.	1.5	8
206	Pylephlebitis complicating silent diverticulitis. Lancet, The, 2006, 368, 422.	6.3	7
207	First appearance of Crohn's disease following infliximab treatment for spondylarthropathy. Scandinavian Journal of Gastroenterology, 2007, 42, 784-785.	0.6	7
208	Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. Alimentary Pharmacology and Therapeutics, 2010, 31, 573-582.	1.9	7
209	Ursodeoxycholic Acid Improves Bilirubin but Not Albumin in Primary Biliary Cirrhosis: Further Evidence for Nonefficacy. BioMed Research International, 2013, 2013, 1-6.	0.9	7
210	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies. Journal of Hepatology, 2017, 66, S593.	1.8	7
211	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2019, 9, CD013120.	1.5	7
212	Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013121.	1.5	7
213	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013157.	1.5	7
214	Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease. Movement Disorders, 0, , .	2.2	7
215	Interventions for hereditary haemochromatosis. The Cochrane Library, 2017, 3, CD011647.	1.5	6
216	Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. The Cochrane Library, 2013, , CD006803.	1.5	5

#	Article	IF	Citations
217	Steatosis affects the sensitivity but not the specificity of nonâ€invasive fibrosis tests in nonâ€alcoholic fatty liver disease â€“ implications for screening strategies. Liver International, 2018, 38, 224-226.	1.9	5
218	Epidemiology of Varices and Variceal Bleeding in Liver Cirrhosis. , 2021, , 1-11.		5
219	Donorâ€“recipient human leukocyte antigen A mismatching is associated with hepatic artery thrombosis, sepsis, graft loss, and reduced survival after liver transplant. Liver Transplantation, 2022, 28, 1306-1320.	1.3	5
220	Prognostic Factors for 10-Year Survival in Patients With Hepatocellular Cancer Receiving Liver Transplantation. Frontiers in Oncology, 2022, 12, 877107.	1.3	5
221	Liver Transplantation in Greek Patients: Epidemiological Data, Morbidity, and Mortality of 71 Patients from a Single Center With 6 Years of Mean Follow-up. Transplantation Proceedings, 2007, 39, 1505-1507.	0.3	4
222	Regression of fibrosis: The need for quantitative methods of assessment. Journal of Hepatology, 2012, 57, 1391.	1.8	4
223	Prognostic Models for Survival in Patients with Stable Cirrhosis: A Multicenter Cohort Study. Digestive Diseases and Sciences, 2017, 62, 1363-1372.	1.1	4
224	Curve Your Enthusiasm: The Decision to Use Expanded or Original Baveno VI Criteria to Exclude High-Risk Varices. Clinical Gastroenterology and Hepatology, 2020, 18, 1243-1244.	2.4	4
225	Elastic fibres in alcoholic liver disease. Scientific Reports, 2020, 10, 20098.	1.6	4
226	Sex is a major effect modifier between body composition and mortality in patients with cirrhosis assessed for liver transplantation. Liver International, 2023, 43, 160-169.	1.9	4
227	Acute ischemic injury due to a giant intrahepatic hematoma: A complication of percutaneous liver biopsy. European Journal of Internal Medicine, 2007, 18, 339-341.	1.0	3
228	Towards a better liver allocation system. Journal of Hepatology, 2009, 51, 827-828.	1.8	3
229	230 SERUM HEPCIDIN LEVELS DEPEND ON AETIOLOGY BUT NOT SEVERITY OF CIRRHOSIS. Journal of Hepatology, 2009, 50, S93.	1.8	3
230	Primary Prevention of Variceal Hemorrhage. Current Gastroenterology Reports, 2011, 13, 3-9.	1.1	3
231	Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardization. Journal of Hepatology, 2013, 58, 194.	1.8	3
232	25 LONG TERM â€“ 8 YEAR FOLLOW UP OF A RANDOMIZED TRIAL OF TACROLIMUS MONOTHERAPY VERSUS TRIPLE THERAPY AFTER LIVER TRANSPLANTATION FOR HCV CIRRHOSIS. Journal of Hepatology, 2013, 58, S11.	1.8	3
233	Liver stiffness measurements increase after meal ingestion - an important step towards standardization. Annals of Hepatology, 2013, 12, 839-840.	0.6	3
234	Glucocorticosteroids for people with alcoholic hepatitis. The Cochrane Library, 0, , .	1.5	3

#	Article	IF	Citations
235	Subtypes and clinical significance of common bile duct varices in portal vein thrombosis: diagnosis and follow-up by Doppler US and EUS. Abdominal Radiology, 2016, 41, 476-484.	1.0	3
236	Primary prevention of bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis. The Cochrane Library, 0, , .	1.5	3
237	Lifestyle modifications for non-alcohol related fatty liver disease: a network meta-analysis. The Cochrane Library, 2018, , .	1.5	3
238	Establishing reliability criteria forLiver ElastPQ Shear-wave Elastography (ElastPQ-SWE): Comparison between 3,5 and 10 measurements. Journal of Hepatology, 2018, 68, S554-S555.	1.8	3
239	SAT-016-Impact of sarcopenia in patients undergoing transjugular intrahepatic portosystemic shunt insertion for refractory ascites. Journal of Hepatology, 2019, 70, e632.	1.8	3
240	Histological subâ€classification of cirrhosis using collagen proportionate area in patients with chronic hepatitis C. Liver International, 2021, 41, 1608-1613.	1.9	3
241	Collagen proportionate area predicts long-term mortality in patients with alcoholic hepatitis. Digestive and Liver Disease, 2022, 54, 663-668.	0.4	3
242	Nutritional supplementation for non-alcohol-related fatty liver disease: a network meta-analysis. The Cochrane Library, 0, , .	1.5	3
243	Comparison of pointâ€shear wave elastography (ElastPQ) and transient elastography (FibroScan) for liver fibrosis staging in patients with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 2195-2203.	1.9	3
244	Hepatobiliary and pancreatic: Spontaneous splenorenal shunts in portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 1214-1214.	1.4	2
245	Adipokines and insulin resistance in chronic hepatitis C. Hepatology, 2007, 46, 2050-2051.	3.6	2
246	Acute splenic sequestration crisis (ASSC) in an adult patient with Î²-thalassemia sickle cell disease: a life-threatening complication. Annals of Hematology, 2008, 87, 499-500.	0.8	2
247	PP-011â€…Collagen proportionate area: a continuous quantitative of histological collagen has the best correlation with transient elastography. Gut, 2010, 59, A44.2-A44.	6.1	2
248	207 MELD VS CPS FOR PROGNOSIS IN CIRRHOSIS. RESULTS FROM A MULTICENTRE STUDY. Journal of Hepatology, 2010, 52, S89.	1.8	2
249	Elastography for Hepatic Fibrosis Severity in Chronic Hepatitis B or C. Case Reports in Gastroenterology, 2011, 5, 63-72.	0.3	2
250	Embolization of porto-systemic shunt as treatment for recurrent hepatic encephalopathy. Annals of Hepatology, 2014, 13, 555-557.	0.6	2
251	Letter: prognostic scores in alcoholic hepatitis - authors' reply. Alimentary Pharmacology and Therapeutics, 2014, 39, 1341-1341.	1.9	2
252	Cost-effectiveness of upcoming treatments for hepatitis C: We need to get the models right. Journal of Hepatology, 2014, 61, 453-454.	1.8	2

#	Article	IF	Citations
253	Forns index and 'FIB4' for staging of fibrosis in adults with chronic hepatitis C. The Cochrane Library, 0, , .	1.5	2
254	Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis. The Lancet Gastroenterology and Hepatology, 2017, 2, 549-550.	3.7	2
255	Validation of the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease: an individual patient meta-analysis. Journal of Hepatology, 2017, 66, S69.	1.8	2
256	Point shear wave elastography (ElastPQ) is a reliable non-invasive tool for the diagnosis and characterisation of portal hypertension. Journal of Hepatology, 2017, 66, S667.	1.8	2
257	Rifaximin treatment for encephalopathy reduces hospital resource use: real-world data donâ€™t fail to IMPRESS. Frontline Gastroenterology, 2017, 8, 230-231.	0.9	2
258	Pharmacological interventions for acute hepatitis C infection. The Cochrane Library, 2018, 12, CD011644.	1.5	2
259	Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2018, , .	1.5	2
260	Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 0, , .	1.5	2
261	Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis. The Cochrane Library, 2018, , .	1.5	2
262	Pediatric NAFLD: lessons from the gut. Hepatobiliary Surgery and Nutrition, 2020, 9, 534-536.	0.7	2
263	Expanding the use of the vibration controlled transient elastography in morbid obese patients: validation of a new automated adaptive measurement depths algorithm in a large pooled NAFLD cohort. Journal of Hepatology, 2020, 73, S430-S431.	1.8	2
264	The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries. Digestive and Liver Disease, 2020, 52, e33-e34.	0.4	2
265	Royal Free Hospitalâ€estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. Liver International, 2021, 41, 819-827.	1.9	2
266	NAFLD: Diagnostic Algorithms for Regulating Patient Fluxes. Current Pharmaceutical Design, 2021, 27, 3036-3046.	0.9	2
267	Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?. Gut, 2021, , gutjnl-2021-325994.	6.1	2
268	Liver stiffness measurements increase after meal ingestion--an important step towards standardization. Annals of Hepatology, 2013, 12, 839-40.	0.6	2
269	Embolization of porto-systemic shunt as treatment for recurrent hepatic encephalopathy. Annals of Hepatology, 2014, 13, 555-7.	0.6	2
270	Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.1	2

#	Article	IF	Citations
271	Binge drinking and fibrogenesis: More than just a hangover. Liver International, 2022, 42, 6-8.	1.9	2
272	[749] SERUM APOPTOTIC CASPASE ACTIVITY AS MARKER OF DISEASE SEVERITY IN CHRONIC HEPATITIS C (CH-C) OR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Journal of Hepatology, 2007, 46, S282.	1.8	1
273	163 ASSESSMENT OF ADRENOCORTICAL RESERVE IN STABLE PATIENTS WITH CIRRHOSIS. Journal of Hepatology, 2010, 52, S71-S72.	1.8	1
274	158 RELIABILITY OF SERUM CREATININE IN ASSESSING RENAL FUNCTION IS DIMINISHED IN PATIENTS WITH CIRRHOSIS AS COMPARED WITH PATIENTS WITH ORGANIC RENAL DISEASE. Journal of Hepatology, 2011, 54, S68-S69.	1.8	1
275	556 SVR AND TACROLIMUS WITH AZATHIOPRINE IN HCV POST LT PATIENTS WERE ASSOCIATED WITH FIBROSIS REGRESSION BASED ON COLLAGEN PROPORTIONATE AREA. Journal of Hepatology, 2011, 54, S227.	1.8	1
276	Does MMF really slow down fibrosis of HCV recurrence in liver transplant recipients?. Transplant International, 2011, 24, e77-e78.	0.8	1
277	O81 COST-EFFECTIVENESS OF NON-INVASIVE LIVER FIBROSIS TESTS FOR TREATMENT DECISIONS IN PATIENTS WITH CHRONIC HEPATITIS C: SYSTEMATIC REVIEW AND ECONOMIC EVALUATION. Journal of Hepatology, 2014, 60, S33.	1.8	1
278	Inflammation-based scores and hepatocellular carcinoma - authors' reply. Liver Transplantation, 2014, 20, n/a-n/a.	1.3	1
279	PTH-119ÂDifferences between radiology and histopathology: are we judging wrong? should we lower alpha-fetoprotein cut-off in the selection criteria?. Gut, 2015, 64, A460.1-A460.	6.1	1
280	Letter: scoring models in alcoholic hepatitis â€“ authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 42, 127-127.	1.9	1
281	P1046 : A one year retrospective review of new patient attendances at a tertiary hepatology centre highlighting the increasing challenge of NAFLD and the need to develop clinical pathways. Journal of Hepatology, 2015, 62, S740.	1.8	1
282	Implications and benefits of the use of rifaximin for preventing episodes of hepatic encephalopathy. British Journal of Health Care Management, 2016, 22, 108-111.	0.1	1
283	Performance of FibroscanÂ® in the Assessment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis Patients: Interim Results of a Prospective Multicentre Validation Study. Journal of Hepatology, 2016, 64, S494.	1.8	1
284	FibroTest, transient elastography method, and combined FibroTest and transient elastography method for diagnosis of severe hepatic fibrosis and cirrhosis in adults with chronic hepatitis C. The Cochrane Library, 2016, , .	1.5	1
285	Non-Selective Beta Blockers (NSBBS) Use is Associated with Improved Survival in Cirrhotic Patients with Ascites: A Single Centre Retrospective Study. Journal of Hepatology, 2016, 64, S668.	1.8	1
286	Pharmacological interventions for acute hepatitis C infection. The Cochrane Library, 2017, 3, CD011644.	1.5	1
287	Collagen proportion area is an independent predictor of longterm outcome in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2017, 66, S52.	1.8	1
288	Primary care sequential use of FIB-4 and the enhanced liver fibrosis test to stratify patients with non-alcoholic fatty liver disease increases cirrhosis detection and reduces referrals of patients with mild disease â€“ 2 year study analysis. Journal of Hepatology, 2017, 66, S68.	1.8	1

#	Article	IF	Citations
289	Reply. Hepatology, 2017, 66, 1361-1362.	3.6	1
290	MRE in NAFLD: Promising but Further Validation is Required. Annals of Hepatology, 2017, 16, 331-332.	0.6	1
291	Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)-development in a large prospective multicenter UK study. Journal of Hepatology, 2018, 68, S552-S553.	1.8	1
292	Loco-regional treatments on the liver transplant waiting list: unmasking hepatocellular carcinoma (HCC) biology. Hepatobiliary Surgery and Nutrition, 2018, 7, 199-201.	0.7	1
293	The use of statins in the management of chronic liver disease. AME Medical Journal, 2018, 3, 3-3.	0.4	1
294	Secondary prevention of bleeding in people with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2018, , .	1.5	1
295	Treatment for ascites in people with decompensated liver cirrhosis: a network meta-analysis. The Cochrane Library, 2018, , .	1.5	1
296	Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. The Cochrane Library, 2018, , .	1.5	1
297	The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis. Journal of Hepatology, 2018, 68, S721-S722.	1.8	1
298	Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: Lessons from a cohort with available liver biopsies. Journal of Hepatology, 2018, 68, S572-S573.	1.8	1
299	Alcohol relapse after liver transplantation: impact of a novel risk assessment scoring system. Journal of Hepatology, 2018, 68, S39.	1.8	1
300	Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes nonâ€alcoholic fatty liver diseaseâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 339-339.	1.9	1
301	THU-309-Cardiovascular risk assessment and management improves outcomes in a specialist multidisciplinary non-alcoholic fatty liver disease clinic. Journal of Hepatology, 2019, 70, e296.	1.8	1
302	SAT-293-Combination of FibroScan and FibroMeter (FibroMeter VCTE) improves identification of patients with advanced fibrosis in patients with NAFLD. Journal of Hepatology, 2019, 70, e766-e767.	1.8	1
303	PS-204-The relationship between FIB-4 progression and liver outcome among patients with type 2 diabetes mellitus: A population based hospital study. Journal of Hepatology, 2019, 70, e136.	1.8	1
304	PTU-041â€…Thromboelastography demonstrates a hypercoagulable profile in cirrhosis and correlates with liver disease severity. , 2019, , .		1
305	Human Immunodeficiency Virus and Fatty Liver: The Perfect Storm or a Storm in a Teacup?. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e25-e26.	0.9	1
306	Reply to: â€œFIB-4 cut off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver diseaseâ€• Journal of Hepatology, 2020, 73, 217-218.	1.8	1

#	Article	IF	Citations
307	Reply to: â€œBaveno VI elastography criteria for ruling in cACLD works well in patients with MAFLDâ€•and â€œTransient elastography in chronic liver disease: Beware of the cut-offs!â€• Journal of Hepatology, 2021, 75, 1247.	1.8	1
308	Reply to: Correspondence on â€œEASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis â€“ 2021 updateâ€• Journal of Hepatology, 2022, 76, 251-252.	1.8	1
309	Is MELD the best prognostic score in acute variceal bleeding? The jury is still out. Annals of Gastroenterology, 2014, 27, 282-283.	0.4	1
310	Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design. The Lancet Gastroenterology and Hepatology, 2022, 7, 586-587.	3.7	1
311	Translation Reprogramming as a Novel Therapeutic Target in MAFLD. Advanced Biology, 2022, , 2101298.	1.4	1
312	478 RECURRENCE PRIMARY BILIARY CIRRHOSIS AFTER LIVER TRANSPLANTATION: THE EFFECT OF AZATHIOPRINE. Journal of Hepatology, 2009, 50, S180.	1.8	0
313	OC-035â€…Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a diagnostic test accuracy meta-analysis. Gut, 2010, 59, A15.1-A15.	6.1	0
314	PTU-058â€…Histological liver collagen proportionate area predicts decompensation in patients with liver cirrhosis of mixed aetiologies. Gut, 2010, 59, A72.1-A72.	6.1	0
315	PTU-074â€…Infection and history of infection are independent of meld for prognosis in cirrhosis. Gut, 2010, 59, A79.1-A79.	6.1	0
316	430 ELASTOGRAPHY FOR THE DIAGNOSIS OF SEVERITY OF FIBROSIS IN CHRONIC LIVER DISEASE. A DIAGNOSTIC TEST ACCURACY META-ANALYSIS. Journal of Hepatology, 2010, 52, S175.	1.8	0
317	481 CPA MEASUREMENT AT ONE YEAR BIOPSY IS HIGHLY PREDICTIVE OF FUTURE CLINICAL DECOMPENSATION IN HCV POST-TRANSPLANT PATIENTS RANDOMIZED IN TACROLIMUS MONOTHERAPY VERSUS TRIPLE THERAPY (TACROLIMUS-BASED). Journal of Hepatology, 2010, 52, S194-S195.	1.8	0
318	200 INFECTION AND HISTORY OF INFECTION ARE INDEPENDENT OF MELD FOR PROGNOSIS IN CIRRHOSIS. Journal of Hepatology, 2010, 52, S86.	1.8	0
319	F-28 Systematic error in MELD calculation by using serum creatinine measurement in cirrhosis. Digestive and Liver Disease, 2011, 43, S100-S101.	0.4	0
320	F-29 Reliability of serum creatinine in assessing renal function is reduced in patients with cirrhosis as compared with patients with organic renal disease. Digestive and Liver Disease, 2011, 43, S101.	0.4	0
321	577 SYSTEMATIC ERROR IN MELD CALCULATION BY USING SERUM CREATININE AND CREATININE-BASED EQUATIONS IN PATIENTS WITH CIRRHOSIS. Journal of Hepatology, 2011, 54, S235.	1.8	0
322	651 RELATIONSHIP BETWEEN FEATURES OF CIRRHOTIC CARDIOMYOPATHY AND ADRENAL DYSFUNCTION IN CIRRHOSIS. Journal of Hepatology, 2012, 56, S258.	1.8	0
323	652 DEVELOPMENT OF A FORMULA TO ESTIMATE GLOMERULAR FILTRATION RATE (GFR) IN PATIENTS WITH CIRRHOSIS. Journal of Hepatology, 2012, 56, S258.	1.8	0
324	PWE-166â€…Hepaticâ€…Artery Embolisation in Neuroendocrine Tumors; Outcomes From a Series of 50 Patients. Gut, 2013, 62, A198.1-A198.	6.1	0

#	Article	IF	Citations
325	P1302 THE OPTIMAL IMMUNOSUPPRESSION REGIMEN FOR DELAYING FIBROSIS PROGRESSION IN HCV AFTER LIVER TRANSPLANTATION. Journal of Hepatology, 2014, 60, S528.	1.8	0
326	P906 AZATHIOPRINE AND EARLY TACROLIMUS LEVELS <10 ng/mL ARE PROTECTIVE AGAINST PROGRESSIVE FIBROSIS IN RECURRENT HCV POST LT. Journal of Hepatology, 2014, 60, S377.	1.8	0
327	P854 PARENCHYMAL MEASURED FAT PROPORTIONATE AREA COULD NOT EXPLAIN THE ABNORMAL TRANSAMINASES IN NAFL PATIENTS. Journal of Hepatology, 2014, 60, S356.	1.8	0
328	P0181 : Development and validation of a mathematical formula to estimate GFR in patients with cirrhosis. Journal of Hepatology, 2015, 62, S371-S372.	1.8	0
329	PWE-085ÂAnalysis of new patient attendances for nafld at three london hospitals highlights the need to develop clinical risk stratification pathways. Gut, 2015, 64, A249.1-A249.	6.1	0
330	PWE-097ÂPharmacological treatments for primary sclerosing cholangitis: a network meta-analysis. Gut, 2015, 64, A254.2-A255.	6.1	0
331	P0387 : Identification of optimal cut-offs in alpha-fetoprotein and the â€œAFP Scoreâ€•to maximise the accuracy of selection of liver transplant candidates with hepatocellular carcinoma. Journal of Hepatology, 2015, 62, S458.	1.8	0
332	Expansion of Access to HBV Treatment. Current Hepatology Reports, 2015, 14, 195-202.	0.4	0
333	PTH-134ÂReduced calcineurin inhibitor exposure early after liver transplantation protects against renal dysfunction independently of the use of basiliximab induction therapy. Gut, 2015, 64, A467.2-A467.	6.1	0
334	P0081 : Reduced calcineurin inhibitor exposure early after liver transplantation protects against renal dysfunction independently of the use of basiliximab induction therapy. Journal of Hepatology, 2015, 62, S323-S324.	1.8	0
335	P1039 : A review of outcomes of liver biopsies in HIV-infected patients without hepatitis co-infection 2002-2012. Journal of Hepatology, 2015, 62, S737.	1.8	0
336	P1126 : Pharmacological treatments for severe alcoholic hepatitis: A network meta-analysis. Journal of Hepatology, 2015, 62, S773.	1.8	0
337	Prevalence and Predictors of the Metabolic Syndrome Post Liver Transplantation. Journal of Hepatology, 2016, 64, S545.	1.8	0
338	National Survey Investigating the Potential Role of Non-Invasive Liver Fibrosis Tests in the UK. Journal of Hepatology, 2016, 64, S716.	1.8	0
339	The Baveno VI Guidelines: Can We Confidently Identify Low Risk Cirrhotic Patients not Requiring Endoscopic Surveillance for Varices?. Journal of Hepatology, 2016, 64, S725.	1.8	0
340	Simple Non Invasive Fibrosis Scores Predict Long Term Mortality in Patients with Non Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S720-S721.	1.8	0
341	Primary Care Sequential Use of FIB-4 and the Enhanced Liver Fibrosis Test to Stratify Patients with Non-alcoholic Fatty Liver Acide Doubles Cirrhosis Detection and Reduces Referrals of Patients with Mild Disease. Journal of Hepatology, 2016, 64, S474-S475.	1.8	0
342	Liver Test Abnormalities in Patients with HIV Mono-Infection: Assessment with Simple Non-Invasive Fibrosis Markers. Journal of Hepatology, 2016, 64, S737-S738.	1.8	0

#	Article	IF	Citations
343	Relationship between Pattern of Hepatic Iron Deposition, Disease Severity and Clinical Outcomes in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S480-S481.	1.8	0
344	The Prevalence and Predictors of Cardiovascular Events Post-Liver Transplantation. Journal of Hepatology, 2016, 64, S545.	1.8	0
345	Case 21-2016: A Man in an Unresponsive State. New England Journal of Medicine, 2016, 375, 1697-1697.	13.9	0
346	Reply to: â€œThe BAVENO VI criteria to identify patients not requiring endoscopic surveillance for esophageal varices â€“ Should We use it?â€• Journal of Hepatology, 2017, 66, 1332-1333.	1.8	0
347	FibroScan-based score to identify patients with non-alcoholic steatohepatitis: development in a multi-centric British cohort and validation in a large American cohort. Journal of Hepatology, 2017, 66, S66-S67.	1.8	0
348	ElastPQ shear-wave elastography compared to fibroscan transient elastography for fibrosis staging in patients with NAFLD. Journal of Hepatology, 2017, 66, S236.	1.8	0
349	Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies. Journal of Hepatology, 2017, 66, S68-S69.	1.8	0
350	The clinical utility of non-invasive tests in cirrhosis: results of decision analysis modelling. Journal of Hepatology, 2017, 66, S660-S661.	1.8	0
351	Cardiovascular risk factors are independent of fibrosis severity in NAFLD. Journal of Hepatology, 2017, 66, S154.	1.8	0
352	Bridging therapies are not detrimental in patients with hepatocellular cancer waiting for liver transplant: A propensity score analysis. Digestive and Liver Disease, 2018, 50, 7-8.	0.4	0
353	Differentiating non-alcoholic steatohepatitis (NASH) from simple steatosis: assessment and validation of novel metabolic markers of non-alcoholic fatty liver disease (NAFLD) severity. Atherosclerosis, 2018, 275, e65.	0.4	0
354	Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH). Journal of Hepatology, 2018, 68, S825-S826.	1.8	0
355	ELF test in NAFLD: Poor concordance with liver stiffness values. Journal of Hepatology, 2018, 68, S572.	1.8	0
356	Cardiovascular risk factors and fibrosisseverity in NAFLD: is there a link?. Journal of Hepatology, 2018, 68, S830.	1.8	0
357	Tacrolimus cumulative exposure after liver transplantation is associated with a progressive derangement of renal function despite routine dose adjustments. Journal of Hepatology, 2018, 68, S377-S378.	1.8	0
358	Collagen proportionate area is an independent predictor of short and long-term survival in patients with alcoholic hepatitis. Journal of Hepatology, 2018, 68, S41.	1.8	0
359	Performance of controlled attenuation parameter (CAP) to assess steatosis in a large prospective multicentre UK study of patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2018, 68, S98.	1.8	0
360	Prediction of early mortality despite liver transplantation in acute liver failure. Journal of Hepatology, 2018, 68, S602.	1.8	0

#	Article	IF	Citations
361	Should age be an absolute contraindication to liver transplantation in acute liver failure?. Journal of Hepatology, 2018, 68, S603.	1.8	0
362	Combined elastin and collagen proportionate area sub-classifies cirrhosis and predicts clinical outcomes. Journal of Hepatology, 2018, 68, S735.	1.8	0
363	Collagen proportionate Ã¡rea is an independent predictor of long term outcome in patients with alcoholic liver disease. Journal of Hepatology, 2018, 68, S811-S812.	1.8	0
364	Comparison of ElastPQ Shear-wave Elastography (ElastPQ-SWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD. Journal of Hepatology, 2018, 68, S554.	1.8	0
365	SAT-108-Sarcopenia and nutritional status predict mortality in patients with cirrhosis undergoing liver transplant assessment. Journal of Hepatology, 2019, 70, e676.	1.8	0
366	SAT-322-Comparison of point shear wave elastography (ElastPQ-pSWE) and FibroScan Transient Elastography (F-TE) for liver fibrosis staging in patients with NAFLD. Journal of Hepatology, 2019, 70, e781-e782.	1.8	0
367	SAT-064-The prognosis following bacterascites is as poor as spontaneous bacterial peritonitis. Journal of Hepatology, 2019, 70, e655-e656.	1.8	0
368	THU-337-Cardiovascular risk factors and fibrosis severity in NAFLD: is there a link?. Journal of Hepatology, 2019, 70, e308.	1.8	0
369	SAT-096-Large spontaneous portosystemic shunt (SPSS) area is associated with hepatic encephalopathy and predicts mortality in liver cirrhosis. Journal of Hepatology, 2019, 70, e670.	1.8	0
370	Editorial: collagen proportionate area as a prognostic indicator in NAFLDâ€"authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1454-1455.	1.9	0
371	Tacrolimus Trough Concentrations After Liver Transplantation: Back to the Future. Transplantation, 2020, 104, e114-e114.	0.5	0
372	Non-alcoholic steatohepatitis (NASH)-related cirrhosis is not associated with lower patient eligibility for liver transplantation compared to other liver disease aetiologies. Journal of Hepatology, 2020, 73, S11-S12.	1.8	0
373	A transcriptomic signature predicting fibrosis progression in a large European cohort of patients with histologically characterised NAFLD. Journal of Hepatology, 2020, 73, S109-S110.	1.8	0
374	A new vision of non-alcoholic fatty liver disease: a â€œcardiacâ€•disease per se and a â€œvascularâ€•disease only with hypertension. Journal of Hepatology, 2020, 73, S144-S145.	1.8	0
375	Myosteatosis and sarcopenia are prevalent in patients with NAFLD even in the absence of advanced fibrosis. Journal of Hepatology, 2020, 73, S149-S150.	1.8	0
376	Individual patient data meta-analysis on controlled attenuation parameter for the XL probe in obese patients. Journal of Hepatology, 2020, 73, S437-S438.	1.8	0
377	Bacterial infections correlate with poor prognosis in cirrhosis independently from liver disease severity. Journal of Hepatology, 2020, 73, S737-S738.	1.8	0
378	A multidisciplinary approach to non-alcoholic fatty liver disease (NAFLD) improves cardiovascular risk factors: the experience of a tertiary liver center in UK. Digestive and Liver Disease, 2020, 52, e46.	0.4	0

#	Article	IF	Citations
379	Definition of healthy ranges for alanine aminotransferase levels: a 2020 update. Digestive and Liver Disease, 2021, 53, S4.	0.4	0
380	Reply to: â€œDo we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?â€• Journal of Hepatology, 2021, 75, 752-753.	1.8	0
381	Reply to: â€œFIB-4 cut-off should be re-evaluated in patients with metabolic associated fatty liver disease (MAFLD)â€• Journal of Hepatology, 2021, 74, 248-249.	1.8	0
382	Response to Debnath and Rathi. American Journal of Gastroenterology, 2021, 116, 1358-1359.	0.2	0
383	Tacrolimus Exposure After Liver Transplantation in Randomized Controlled Trials: Too Much for Too Long. American Journal of Transplantation, 2013, , n/a-n/a.	2.6	0
384	Defining Clinical Hints to Predict Decompensation and Altering Paradigm in Patients with Cirrhosis. , 2016, , 89-97.		0
385	The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries. , 2020, 58, .		0
386	Response to Anand and Sharma. American Journal of Gastroenterology, 2021, 116, 1094-1095.	0.2	0
387	Editorial overview: The treatment of liver diseases in 2020â€“2030. Current Opinion in Pharmacology, 2022, 62, 1-3.	1.7	0
388	Development and validation of a deep learning model for the prediction of hepatocellular cancer recurrence after transplantation: an international study. Digestive and Liver Disease, 2022, 54, S9.	0.4	0
389	Editorial: can quantitative fibrosis assessment be used to enhance prediction of outcomes in patients with alcoholâ€related liver disease? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 185-186.	1.9	0
390	Biomarkers for brain injury and copper toxicity in Wilsonâ€™s disease: a diffusion tensor imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A94.1-A94.	0.9	0